SEGMENT INFORMATION (Tables)

12 Months Ended

Dec. 31, 2020

Segment revenues and profits for the years 2020, 2019 and 2018 were as follows:


(in millions)	2020		2019		2018
Revenues:
Bausch + Lomb/International	$	4,408	$	4,739	$	4,664
Salix	1,904		2,022		1,749
Ortho Dermatologics	553		565		617
Diversified Products	1,162		1,275		1,350
Total revenues	$	8,027	$	8,601	$	8,380
Segment profit:
Bausch + Lomb/International	$	1,159	$	1,332	$	1,330
Salix	1,338		1,349		1,149
Ortho Dermatologics	233		222		257
Diversified Products	848		932		1,012
Total segment profit	3,578		3,835		3,748
Corporate	(619)		(609)		(605)
Amortization of intangible assets	(1,645)		(1,897)		(2,644)
Goodwill impairments	—		—		(2,322)
Asset impairments, including loss on assets held for sale	(114)		(75)		(568)
Restructuring, integration and separation costs	(22)		(31)		(22)
Acquisition-related contingent consideration	(48)		(12)		9
Other (expense) income, net	(454)		(1,414)		20
Operating income (loss)	676		(203)		(2,384)
Interest income	13		12		11
Interest expense	(1,534)		(1,612)		(1,685)
Loss on extinguishment of debt	(59)		(42)		(119)
Foreign exchange and other	(30)		8		23
Loss before benefit from income taxes	$	(934)	$	(1,837)	$	(4,154)

Schedule of capital expenditures, depreciation and amortization by segment

Capital expenditures by segment for the years 2020, 2019 and 2018 were as follows:


(in millions)	2020		2019		2018
Capital expenditures:
Bausch + Lomb/International	$	282	$	225	$	139
Salix	3		2		2
Ortho Dermatologics	2		1		1
Diversified Products	2		2		2
	289		230		144
Corporate	13		40		13
Total capital expenditures	$	302	$	270	$	157

Schedule of revenues by product and by product category

Revenues by segment and product category were as follows:


(in millions)	Bausch + Lomb/ International						Salix						Ortho Dermatologics						Diversified Products						Total
	2020		2019		2018		2020		2019		2018		2020		2019		2018		2020		2019		2018		2020		2019		2018
Pharmaceuticals	$	759	$	885	$	892	$	1,899	$	2,022	$	1,752	$	279	$	355	$	457	$	741	$	810	$	927	$	3,678	$	4,072	$	4,028
Devices	1,313		1,524		1,505		—		—		—		253		193		135		—		—		—		1,566		1,717		1,640
OTC	1,432		1,452		1,412		—		—		—		—		—		—		—		—		—		1,432		1,452		1,412
Branded and Other Generics	838		801		784		—		—		—		—		—		—		410		447		407		1,248		1,248		1,191
Other revenues	66		77		71		5		—		(3)		21		17		25		11		18		16		103		112		109
	$	4,408	$	4,739	$	4,664	$	1,904	$	2,022	$	1,749	$	553	$	565	$	617	$	1,162	$	1,275	$	1,350	$	8,027	$	8,601	$	8,380

Schedule of revenues and long-lived assets by geographic region

Revenues are attributed to a geographic region based on the location of the customer for the years 2020, 2019 and 2018 were as follows:


(in millions)	2020		2019		2018
U.S. and Puerto Rico	$	4,791	$	5,164	$	5,011
China	341		368		361
Canada	331		339		319
Egypt	243		218		178
Poland	238		231		218
Japan	226		241		226
Mexico	225		228		211
France	179		201		205
Germany	144		150		170
Russia	137		180		154
United Kingdom	86		115		117
Spain	78		86		83
Other	1,008		1,080		1,127
	$	8,027	$	8,601	$	8,380

Schedule of assets by geographic region

Long-lived assets consisting of property, plant and equipment, net of accumulated depreciation, are attributed to geographic regions based on their physical location as of December 31, 2020 and 2019 were as follows:


(in millions)	2020		2019
U.S. and Puerto Rico	$	725	$	656
Ireland	328		255
Canada	110		103
Poland	83		90
Germany	80		68
Mexico	49		50
France	34		30
China	31		27
Serbia	30		27
Italy	23		22
Other	74		138
	$	1,567	$	1,466

Schedule of external customers that accounted for 10% or more of total revenues

Customers that accounted for 10% or more of total revenues were as follows:


	2020	2019	2018
McKesson Corporation	17%	17%	18%
AmerisourceBergen Corporation	17%	16%	18%
Cardinal Health, Inc.	13%	14%	13%